Midazolam nanocrystal facilitates submandibular lymphatic metabolism via cAMP signal transduction pathway

Abstract

Midazolam is a short-acting benzodiazepine for sedation, but its application is limited by its poor solubility. This study explored the impact of midazolam nanocrystals on Cyclic adenosine monophosphate (cAMP0 signal transduction. A rat model of hypercalcemia was established and divided into model group, control group, midazolam nanocrystal group, midazolam group, inhibitor group and agonist group. After treatment, the contents of cAMP and cGMP were detected by radioimmunoassay, and transformation rate, proliferation and apoptosis of lymphocytes were analyzed. Additionally, we observed microcirculation of lymphocytes and calculated contraction activity, overall lymphatic contractile activity and lymph dynamic index. The structure of the prepared nanocrystals was uniform and stable. Higher cGMP concentration and lymph viscosity of rats in the midazolam nanocrystal, midazolam and inhibitor groups were lower, while cGMP was raised in the agonist group. Besides, modeled rats exhibited decreased cAMP concentration, T lymphocyte conversion rate, lymphatic vessel contraction frequency, contraction activity index, total contraction activity index, lymph dynamic index/flow and lymphocyte output (p < 0.05), which were all increased in the midazolam nanocrystal group, midazolam group and agonist group but decreased in the inhibitor group (p < 0.05). Moreover, Midazolam nanocrystals improved lymphocyte proliferation and decreased apoptosis (<0.05). Midazolam nanocrystals can increase the concentration of cAMP and conversion rate of T lymphocytes, thereby reducing the concentration of cGMP, promoting lymphocyte proliferation, inhibiting apoptosis, and effectively improving the contraction frequency and contraction activity of lymphatic vessels. The cGMP can elevate total contractile activity index and lymph dynamics index, and enhance lymphatic transport function, while reducing lymph viscosity.